QuantiFERON-TB Gold for TB Diagnosis
Yes, QuantiFERON-TB Gold is FDA-approved and recommended by CDC for diagnosing Mycobacterium tuberculosis infection, including both latent tuberculosis infection (LTBI) and active tuberculosis disease. 1
What QuantiFERON-TB Gold Actually Does
The test is an interferon-gamma release assay (IGRA) that detects M. tuberculosis infection by measuring interferon-gamma released from sensitized white blood cells when exposed to TB-specific antigens (ESAT-6 and CFP-10). The test received FDA approval in May 2005 as an aid for diagnosing both LTBI and active TB disease 1, distinguishing it from the original QuantiFERON-TB test which was only approved for LTBI.
Clinical Applications
According to CDC guidelines, QuantiFERON-TB Gold may be used in all circumstances where the tuberculin skin test (TST) is currently used, including: 1
- Contact investigations
- Evaluation of recent immigrants
- Sequential-testing surveillance programs (e.g., healthcare workers)
- Screening before biological therapy 2
The updated 2010 CDC guidelines confirm that IGRAs (including QuantiFERON tests) may be used as aids in diagnosing M. tuberculosis infection for both surveillance purposes and to identify persons likely to benefit from treatment 3.
Key Advantages Over TST
The test offers greater specificity than TST because the antigens used are absent from all BCG vaccine strains and most nontuberculous mycobacteria (except M. kansasii, M. szulgai, and M. marinum) 1, 4. This makes it particularly valuable in BCG-vaccinated populations where TST specificity is compromised 2.
Additional practical benefits include:
- Results available in <24 hours without requiring a second visit 1
- No reader bias or placement errors inherent to TST 1
- Single blood draw eliminates patient return visits
Diagnostic Performance
In direct comparisons, the sensitivity of QuantiFERON-TB Gold was statistically similar to TST for detecting infection in persons with untreated culture-confirmed tuberculosis 1. More recent meta-analyses show:
- Pooled sensitivity for active TB: 94% 5
- Pooled specificity for healthy status: 96% 5
- Pooled sensitivity for LTBI: 91% 5
The newer QuantiFERON-TB Gold Plus version demonstrates high agreement (94%) with the In-Tube version, with similar concordance to TST (77%) and T-SPOT (92%) 6.
Important Caveats and Limitations
The test's ability to predict who will eventually develop active TB disease has not been determined, and years of observational study would be needed to acquire this information 1. This is a critical limitation—the test identifies infection but cannot stratify progression risk.
Borderline Results
A borderline range (0.20-0.99 IU/ml) exists around the standard cutoff (0.35 IU/ml). More than one-third of patients with borderline results are convincingly negative upon retesting, without developing incident active TB 7. Consider repeat testing for borderline results rather than immediately initiating treatment.
Indeterminate Results
Indeterminate results occur in approximately 1.6% of tests 7 and are defined as:
- Lack of response in mitogen control (IFN-γ ≤0.5 IU/ml)
- Very high background in nil control (IFN-γ >8 IU/ml)
Negative Results Require Caution
CDC guidelines provide specific cautions for interpreting negative results in selected populations 1. The test may have reduced sensitivity in immunocompromised individuals, though specific guidance varies by clinical context.
Monitoring Treatment Response
Serial QuantiFERON testing shows significant decline in interferon-gamma responses from baseline to 2 months of treatment (median 6.32 vs 4.12 IU/ml, p<0.005), with 87.2% of patients showing decreased responses 8. This supports its potential use for monitoring treatment efficacy, though this is not its primary FDA-approved indication.
Real-World Performance in BCG-Vaccinated Populations
In a Turkish cohort where BCG vaccination is universal, using QuantiFERON-TB Gold In-Tube alone for latent TB screening before biological therapy resulted in TB incidence of 147/100,000 patient-years—approximately seven times the national rate but within acceptable limits for immunosuppressed populations 2. This demonstrates the test's utility in BCG-vaccinated countries where TST specificity is compromised.
Bottom Line for Clinical Practice
Use QuantiFERON-TB Gold as a diagnostic aid for M. tuberculosis infection in any situation where you would use TST, with particular advantage in BCG-vaccinated individuals. The test identifies infection but does not predict disease progression. For borderline results (0.20-0.99 IU/ml), consider repeat testing. The test can supplement but does not replace clinical judgment, radiographic findings, and microbiological confirmation for diagnosing active TB disease.